Synovial Sarcoma - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Synovial Sarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Synovial Sarcoma - Pipeline Review, H2 2016', provides an overview of the Synovial Sarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
- The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Synovial Sarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Synovial Sarcoma - Overview 9
Pipeline Products for Synovial Sarcoma - Comparative Analysis 10
Synovial Sarcoma - Therapeutics under Development by Companies 11
Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 12
Synovial Sarcoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Synovial Sarcoma - Products under Development by Companies 16
Synovial Sarcoma - Products under Investigation by Universities/Institutes 17
Synovial Sarcoma - Companies Involved in Therapeutics Development 18
Adaptimmune Therapeutics Plc 18
Advenchen Laboratories, LLC 19
EpiZyme, Inc. 20
Immune Design Corp. 21
Immunocore Limited 22
Karyopharm Therapeutics, Inc. 23
Merck & Co., Inc. 24
Millennium Pharmaceuticals Inc 25
Novartis AG 26
OncoTherapy Science, Inc. 27
Pfizer Inc. 28
Takara Bio Inc. 29
Synovial Sarcoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
ACXT-3102 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AL-3818 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
axitinib - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CMB-305 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
everolimus - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
GSK-3377794 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
OTSA-101 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
pembrolizumab - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Recombinant Protein for Oncology - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Recombinant Proteins 1 for Oncology - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
sapanisertib - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
selinexor - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
SSTC-104 - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
tazemetostat - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
TBI-1301 - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
Synovial Sarcoma - Discontinued Products 134
Synovial Sarcoma - Product Development Milestones 135
Featured News & Press Releases 135
Feb 22, 2016: The completion of phase I clinical study of the anti-cancer therapeutic antibody 'OTSA101' against synovial sarcoma 135
Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors 135
Aug 24, 2015: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma 136
Oct 17, 2014: Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma 138
Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US 139
Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101 139
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 140
Disclaimer 141

List of Tables

Number of Products under Development for Synovial Sarcoma, H2 2016 9
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 18
Synovial Sarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 19
Synovial Sarcoma - Pipeline by EpiZyme, Inc., H2 2016 20
Synovial Sarcoma - Pipeline by Immune Design Corp., H2 2016 21
Synovial Sarcoma - Pipeline by Immunocore Limited, H2 2016 22
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 23
Synovial Sarcoma - Pipeline by Merck & Co., Inc., H2 2016 24
Synovial Sarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 25
Synovial Sarcoma - Pipeline by Novartis AG, H2 2016 26
Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2016 27
Synovial Sarcoma - Pipeline by Pfizer Inc., H2 2016 28
Synovial Sarcoma - Pipeline by Takara Bio Inc., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Synovial Sarcoma - Discontinued Products, H2 2016 134